The Relationship of Vitamin D and IL-17 Levels with Disease Severity in Pediatric Tuberculosis Patients-Scilight

Trends in Immunotherapy

Article

The Relationship of Vitamin D and IL-17 Levels with Disease Severity in Pediatric Tuberculosis Patients

Downloads

https://doi.org/10.54963/ti.v9i2.1115
Olivianto, E., Mustofa Aidid, & Iskandar, A. (2025). The Relationship of Vitamin D and IL-17 Levels with Disease Severity in Pediatric Tuberculosis Patients. Trends in Immunotherapy, 9(2), 60–72. https://doi.org/10.54963/ti.v9i2.1115
Volume 9 Issue 2 (2025): (in progress)
Copyright (c) 2025 Ery Olivianto, Mustofa Aidid, Agustin Iskandar
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Ery Olivianto

    Department of Child Health, Faculty of Medicine, Universitas Brawijaya‑Dr. Saiful Anwar Hospital, Malang 65112, Indonesia
  • Mustofa Aidid

    Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya‑Dr. Saiful Anwar Hospital, Malang 65112, Indonesia
  • Agustin Iskandar

    Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya‑Dr. Saiful Anwar Hospital, Malang 65112, Indonesia

Tuberculosis (TB) remains a significant global health burden, particularly in children, where immune responses play a crucial role in disease progression. The objective of this research was to analyze the relationship of vitamin D and IL-17 levels with the severity of pediatric TB. This observational analytic study was conducted at Dr. Saiful Anwar Hospital, Malang, involving 33 pediatric patients diagnosed with TB, divided into mild (n = 8), moderate (n = 18) and severe (n = 7) groups. Severity was determined using the score developed in this study. Vitamin D levels were measured using the Cobas c501 analyzer, and IL-17 levels were measured using the Human IL-17 ELISA Kit. While Vitamin D level was significantly lower in microbiologically confirmed patients (p = 0.038), it was not significantly different among severity groups (p = 0.799). Meanwhile, IL-17 levels were significantly higher in patients with more severe respiratory distress (p = 0.01), although the difference between severity groups was not statistically significant (p = 0.966). Furthermore, there was no correlation between vitamin D levels and IL-17 levels (r = 0.178, p = 0.322). These findings indicate the need for further research to explore vitamin D supplementation as an adjunctive therapy and to evaluate IL-17 as a biomarker for disease activity.

Keywords:

Pediatric TB; Vitamin D Deficiency; Interleukin-17; TB Severity; Biomarkers; Immune Modulation

References

  1. World Health Organization. Global Tuberculosis Report 2024. World Health Organization: Geneva, Switzerland, 2024.
  2. World Health Organization. TB Incidence. World Health Organization: Geneva, Switzerland, 2024. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024/tb-disease-burden/1-1-tb-incidence (cited 10 November 2024).
  3. Maphalle, L.N.F.; Michniak-Kohn, B.B.; Ogunrombi, M.O.; et al. Pediatric tuberculosis management: A global challenge or breakthrough? Children 2022, 9, 1120. DOI: https://doi.org/10.3390/children9081120
  4. Carvalho, A.C.C.; Cardoso, C.A.A.; Martire, T.M.; et al. Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy. J. Bras. Pneumol. 2018, 44, 134–144. DOI: https://doi.org/10.1590/s1806-37562017000000461
  5. World Health Organization. WHO Operational Handbook on Tuberculosis. Module 5: Management of Tuberculosis in Children and Adolescents. World Health Organization: Geneva, Switzerland, 2022.
  6. Moore, B.K.; Graham, S.M.; Nandakumar, S.; et al. Pediatric tuberculosis: A review of evidence-based best practices for clinicians and health care providers. Pathogens 2024, 13, 467. DOI: https://doi.org/10.3390/pathogens13060467
  7. Palmer, M.; Seddon, J.A.; Goussard, P.; et al. Diagnostic CXR Atlas for Tuberculosis in Children: A Guide to Chest X-Ray Interpretation, 2nd ed.; International Union Against Tuberculosis and Lung Disease (The Union): Paris, France, 2022.
  8. Moule, M.G.; Cirillo, J.D. Mycobacterium tuberculosis dissemination plays a critical role in pathogenesis. Front. Cell Infect. Microbiol. 2020, 10, 65. DOI: https://doi.org/10.3389/fcimb.2020.00065
  9. Lyadova, I.V.; Panteleev, A.V. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflamm. 2015, 2015, 854507. DOI: https://doi.org/10.1155/2015/854507
  10. Coulter, F.; Parrish, A.; Manning, D.; et al. IL-17 production from T helper 17, mucosal-associated invariant T, and γδ cells in tuberculosis infection and disease. Front. Immunol. 2017, 8, 1252. DOI: https://doi.org/10.3389/fimmu.2017.01252
  11. Luo, J.; Zhang, M.; Yan, B.; et al. Imbalance of Th17 and Treg in peripheral blood mononuclear cells of active tuberculosis patients. Braz. J. Infect. Dis. 2017, 21, 155–161. DOI: https://doi.org/10.1016/j.bjid.2016.10.011
  12. Papagni, R.; Pellegrino, C.; Di Gennaro, F.; et al. Impact of vitamin D in prophylaxis and treatment in tuberculosis patients. Int. J. Mol. Sci. 2022, 23, 3860. DOI: https://doi.org/10.3390/ijms23073860
  13. Al-Jaberi, F.A.H.; Crone, C.G.; Lindenstrøm, T.; et al. Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report. Front. Immunol. 2022, 13, 1038960. DOI: https://doi.org/10.3389/fimmu.2022.1038960
  14. Junaid, K.; Rehman, A. Impact of vitamin D on infectious disease-tuberculosis-a review. Clin. Nutr. Exp. 2019, 25, 1–10. DOI: https://doi.org/10.1016/j.yclnex.2019.02.003
  15. Buonsenso, D.; Pata, D.; Colonna, A.T.; et al. Vitamin D and tuberculosis in children: A role in the prevention or treatment of the disease? Monaldi Arch. Chest Dis. 2022, 92, 2112. DOI: https://doi.org/10.4081/monaldi.2022.2112
  16. Ganmaa, D.; Uyanga, B.; Zhou, X.; et al. Vitamin D supplements for prevention of tuberculosis infection and disease. N. Engl. J. Med. 2020, 383, 359–368. DOI: https://doi.org/10.1056/NEJMoa1915176
  17. Ganmaa, D.; Munkhzul, B.; Fawzi, W.; et al. High-dose vitamin D₃ during tuberculosis treatment in Mongolia. A randomized controlled trial. Am. J. Respir. Crit. Care Med. 2017, 196, 628–637. DOI: https://doi.org/10.1164/rccm.201705-0936OC
  18. Roya-Pabon, C.L.; Perez-Velez, C.M. Tuberculosis exposure, infection and disease in children: a systematic diagnostic approach. Pneumonia 2016, 8, 23. DOI: https://doi.org/10.1186/s41479-016-0023-9
  19. Sarkar, K.; Kashyap, B.; Lnu, S.; et al. Utility of a clinical scoring system (Bandim TB Score and Karnofsky Performance Score) to assess mycobacterial burden in terms of cartridge-based nucleic acid amplification test (CBNAAT) cycle threshold values among pulmonary TB patients. Cureus 2023, 15, e50976. DOI: https://doi.org/10.7759/cureus.50976
  20. Awang, H.; Husain, N.R.N.; Abdullah, H. Chest radiographic findings and clinical determinants for severe pulmonary tuberculosis among children and adolescents in Malaysia. Russ. Open Med. J. 2019, 8, e0210. DOI: https://doi.org/10.15275/rusomj.2019.0210
  21. Chabala, C.; Roucher, C.; Ton Nu Nguyet, M.H.; et al. Development of tuberculosis treatment decision algorithms in children below 5 years hospitalised with severe acute malnutrition in Zambia and Uganda: A prospective diagnostic cohort study. EClinicalMedicine 2024, 73, 102688. DOI: https://doi.org/10.1016/j.eclinm.2024.102688
  22. Ockenga, J.; Fuhse, K.; Chatterjee, S.; et al. Tuberculosis and malnutrition: The European perspective. Clin. Nutr. 2023, 42, 486–492. DOI: https://doi.org/10.1016/j.clnu.2023.01.016
  23. Sinha, P.; Davis, J.; Saag, L.; et al. Undernutrition and tuberculosis: Public health implications. J. Infect. Dis. 2019, 219, 1356–1363. DOI: https://doi.org/10.1093/infdis/jiy675
  24. Vonasek, B.J.; Radtke, K.K.; Vaz, P.; et al. Tuberculosis in children with severe acute malnutrition. Expert Rev. Respir. Med. 2022, 16, 273–284. DOI: https://doi.org/10.1080/17476348.2022.2043747
  25. Acen, E.L.; Biraro, I.A.; Worodria, W.; et al. Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: A systematic review and meta-analysis. PLoS ONE 2021, 16, e0252762. DOI: https://doi.org/10.1371/journal.pone.0252762
  26. Zittermann, A.; Pilz, S.; Hoffmann, H.; et al. Vitamin D and airway infections: a European perspective. Eur. J. Med. Res. 2016, 21, 14. DOI: https://doi.org/10.1186/s40001-016-0208-y
  27. Gou, X.; Pan, L.; Tang, F.; et al. The association between vitamin D status and tuberculosis in children: A meta-analysis. Medicine (Baltimore) 2018, 97, e12179. DOI: https://doi.org/10.1097/md.0000000000012179
  28. Zeng, J.; Wu, G.; Yang, W.; et al. A serum vitamin D level <25nmol/l pose high tuberculosis risk: a meta-analysis. PLoS ONE 2015, 10, e0126014. DOI: https://doi.org/10.1371/journal.pone.0126014
  29. Farazi, A.; Didgar, F.; Sarafraz, A. The effect of vitamin D on clinical outcomes in tuberculosis. Egypt. J. Chest Dis. Tuberc. 2017, 66, 419–423. DOI: https://doi.org/10.1016/j.ejcdt.2017.01.004
  30. Ma, W.-W.; Wang, L.-C.; Zhao, D.-A.; et al. Analysis of T-lymphocyte subsets and risk factors in children with tuberculosis. Tuberculosis 2024, 146, 102496. DOI: https://doi.org/10.1016/j.tube.2024.102496
  31. Jiang, J.; Cao, Z.; Li, B.; et al. Disseminated tuberculosis is associated with impaired T cell immunity mediated by non-canonical NF-κB pathway. J. Infect. 2024, 89, 106231. DOI: https://doi.org/10.1016/j.jinf.2024.106231
  32. Elsafi, S.S.M.S.; Nour, B.M.; Abakar, A.D.; et al. Vitamin D level and it is association with the severity of pulmonary tuberculosis in patients attended to Kosti Teaching Hospital, Sudan. AIMS Microbiol. 2020, 6, 65–74. DOI: https://doi.org/10.3934/microbiol.2020004
  33. Zhang, X.; Zhang, Y.; Yin, Z.; et al. Relationship between vitamin D receptor gene polymorphisms and second acid-fast bacilli smear-positive during treatment for tuberculosis patients. Infect. Genet. Evol. 2022, 103, 105324. DOI: 10.1016/j.meegid.2022.105324
  34. Abohashrh, M.; Ahmad, I.; Alam, M.M.; et al. Assessment of IL-12, mRNA expression, vitamin-D level, and their correlation among the Mycobacterium tuberculosis cases. Saudi J. Biol. Sci. 2022, 29, 992–997. DOI: https://doi.org/10.1016/j.sjbs.2021.10.002
  35. Harishankar, M.; Sampath, P.; Athikesavan, V.; et al. Association of rs7041 and rs4588 polymorphisms of vitamin D binding protein gene in pulmonary tuberculosis. Meta Gene 2020, 26, 100822. DOI: https://doi.org/10.1016/j.mgene.2020.100822
  36. Semita, I.N.; Fatmawati, H.; Munawir, A.; et al. Complete neurological recovery of spinal tuberculosis after spinal surgery and vitamin D supplementary: A case series. Int. J. Surg. Case Rep. 2024, 122, 110053. DOI: https://doi.org/10.1016/j.ijscr.2024.110053
  37. Hassanein, E.G.; Mohamed, E.E.; Baess, A.I.; et al. The role of supplementary vitamin D in treatment course of pulmonary tuberculosis. Egypt. J. Chest Dis. Tuberc. 2016, 65, 629–635. DOI: https://doi.org/10.1016/j.ejcdt.2016.03.004
  38. Ritter, K.; Behrends, J.; Rückerl, D.; et al. High-dose Mycobacterium tuberculosis H37rv infection in IL-17A- and IL-17A/F-deficient mice. Cells 2022, 11, 2875. DOI: https://doi.org/10.3390/cells11182875
  39. Xu, L.; Cui, G.; Jia, H.; et al. Decreased IL-17 during treatment of sputum smear-positive pulmonary tuberculosis due to increased regulatory T cells and IL-10. J. Transl. Med. 2016, 14, 179. DOI: https://doi.org/10.1186/s12967-016-0909-6
  40. Shu, C.-C.; Wu, M.-F.; Wang, J.-Y.; et al. Decreased T helper 17 cells in tuberculosis is associated with increased percentages of programmed death ligand 1, T helper 2 and regulatory T cells. Respir. Res. 2017, 18, 128. DOI: https://doi.org/10.1186/s12931-017-0580-3
  41. Rodríguez-Míguez, Y.; Lozano-Ordaz, V.; Ortiz-Cabrera, A.E.; et al. Effect of IL-17A on the immune response to pulmonary tuberculosis induced by high- and low-virulence strains of Mycobacterium bovis. PLOS ONE 2024, 19, e0307307. DOI: https://doi.org/10.1371/journal.pone.0307307
  42. Mourik, B.C.; Lubberts, E.; de Steenwinkel, J.E.M.; et al. Interactions between type 1 interferons and the Th17 response in tuberculosis: Lessons learned from autoimmune diseases. Front. Immunol. 2017, 8, 294. DOI: https://doi.org/10.3389/fimmu.2017.00294
  43. Kumar, N.P.; Moideen, K.; Banurekha, V.V.; et al. Plasma proinflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis. Open Forum Infect. Dis. 2019, 6, ofz257. DOI: https://doi.org/10.1093/ofid/ofz257
  44. Sharma, P.; Sharma, R.D.; Das, M.; et al. Ly6G⁺Granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis. eLife 2024, 13, RP100966. DOI: https://doi.org/10.7554/elife.100966.1
  45. Kim, T.O.; Park, K.J.; Cho, Y.N.; et al. Altered distribution, activation and increased IL-17 production of mucosal-associated invariant T cells in patients with acute respiratory distress syndrome. Thorax 2022, 77, 865–872. DOI: https://doi.org/10.1136/thoraxjnl-2021-217724
  46. Feng, J.-Y.; Ho, L.-I.; Chuang, F.-Y.; et al. Depression and recovery of IL-17A secretion in mitogen responses in patients with active tuberculosis—a prospective observational study. J. Formos Med. Assoc. 2021, 120, 1080–1089. DOI: https://doi.org/10.1016/j.jfma.2020.09.012
  47. Yeh, W.I.; McWilliams, I.L.; Harrington, L.E. IFNγ inhibits Th17 differentiation and function via Tbet-dependent and Tbet-independent mechanisms. J. Neuroimmunol. 2014, 267, 20–27. DOI: https://doi.org/10.1016/j.jneuroim.2013.12.001
  48. Cervantes, J.L.; Oak, E.; Garcia, J.; et al. Vitamin D modulates human macrophage response to Mycobacterium tuberculosis DNA. Tuberculosis (Edinb) 2019, 116, S131–S137. DOI: https://doi.org/10.1016/j.tube.2019.04.021
  49. Gough, M.E.; Graviss, E.A.; May, E.E. The dynamic immunomodulatory effects of vitamin D₃ during mycobacterium infection. Innate Immun. 2017, 23, 506–523. DOI: https://doi.org/10.1177/1753425917719143
  50. Corrado, A.; Rotondo, C.; Sanpaolo, E.R.; et al. 1,25OH-vitamin D₃ and IL-17 inhibition modulate pro-fibrotic cytokines production in peripheral blood mononuclear cells of patients with systemic sclerosis. Int. J. Med. Sci. 2022, 19, 867–877. DOI: https://doi.org/10.7150/ijms.70984
  51. Wang, W.; Deng, G.; Zhang, G.; et al. Genetic polymorphism rs8193036 of IL17A is associated with increased susceptibility to pulmonary tuberculosis in Chinese Han population. Cytokine 2020, 127, 154956. DOI: https://doi.org/10.1016/j.cyto.2019.154956
  52. Pollara, G.; Turner, C.T.; Rosenheim, J.; et al. Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. Sci. Transl. Med. 2021, 13, eabg7673. DOI: https://doi.org/10.1126/scitranslmed.abg7673